MBX Stock Overview
A clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
MBX Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$18.50 |
| 52 Week High | US$27.50 |
| 52 Week Low | US$15.31 |
| Beta | 0 |
| 11 Month Change | -12.90% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -21.78% |
Recent News & Updates
Shareholder Returns
| MBX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 12.7% | 1.6% | 2.2% |
| 1Y | n/a | 9.9% | 31.6% |
Return vs Industry: Insufficient data to determine how MBX performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how MBX performed against the US Market.
Price Volatility
| MBX volatility | |
|---|---|
| MBX Average Weekly Movement | 11.1% |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: MBX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine MBX's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 38 | Peter Hawryluk | mbxbio.com |
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery.
MBX Biosciences, Inc. Fundamentals Summary
| MBX fundamental statistics | |
|---|---|
| Market cap | US$618.22m |
| Earnings (TTM) | -US$55.18m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-11.2x
P/E RatioIs MBX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MBX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$55.18m |
| Earnings | -US$55.18m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.65 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did MBX perform over the long term?
See historical performance and comparison